In addition to amplification, intragenic insertional mutations of HER2 are observed in 4% of lung cancers [5], and its kinase domain mutations are observed in 5% of gastric carcinomas, 2.9% of colorectal carcinomas and 4.3% of breast carcinomas [6]. Here, ERBB2 is linked to lung carcinoma.